| Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. | |
| | |
MedLine Citation:
|
PMID: 2892568 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Concentrations of gamma-aminobutyric acid (GABA), glutamate, aspartate, and taurine were measured in postmortem tissue from the brains of patients with Huntington's disease (HD) and in the quinolinic acid (QA) lesioned rat striatum. The aim of the study was to assess further the ability of the QA model of HD to reproduce the neurochemical features of the disease. Nine cortical and 9 subcortical regions were examined from 17 pathologically graded cases of HD and 10 controls. Significant reductions in both GABA and glutamate were found in HD striatum. The reductions were greater in the more severely affected grades of HD, and there was a gradient of amino acid loss across the striatal nuclei (caudate greater than putamen greater than nucleus accumbens) which was consistent with the known pattern of pathological involvement. Taurine and aspartate concentrations showed no significant change. GABA reductions were found in both segments of the globus pallidus (external greater than internal) and both parts of the substantia nigra (reticulata greater than compacta). In advanced cases of HD, there were significant reductions in glutamate in Brodmann cortical areas 3-1-2, 6, 9, and 17, but GABA, aspartate, and taurine were unaltered in the cortex. The QA lesions reproduced the striatal deficits of both GABA and glutamate but, in contrast to HD, there was a decrease in taurine, possibly due to species differences. Chronic QA lesions resulted in a secondary dying back of corticostriatal glutamatergic terminals, but did not produce a change in cortical glutamate concentration. This suggests that reductions in cortical glutamate in HD may reflect a primary loss of glutamatergic neurons. Our findings extend previous observations on amino acid neurotransmitters in HD and, with the exception of taurine, confirm the general applicability of the QA model. |
| | |
Authors:
|
D W Ellison; M F Beal; M F Mazurek; J R Malloy; E D Bird; J B Martin |
Related Documents
:
|
11238978 - Escherichia coli acid resistance: camp receptor protein and a 20 bp cis-acting sequence... 7097288 - Characterization of glutamic acid decarboxylase activity in cerebral blood vessels. 2870048 - Effects of l-aspartate and oxaloacetic acid on click-evoked cochlear potentials. 2501608 - Valproate doubles the anoxic survival time of normal developing mice: possible relevanc... 22953908 - Degreening and postharvest storage influences 'star ruby' grapefruit (citrus paradisi m... 1122658 - Plasma free fatty acid turnover in total lipodystrophy. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Brain : a journal of neurology Volume: 110 ( Pt 6) ISSN: 0006-8950 ISO Abbreviation: Brain Publication Date: 1987 Dec |
Date Detail:
|
Created Date: 1988-03-07 Completed Date: 1988-03-07 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0372537 Medline TA: Brain Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 1657-73 Citation Subset: AIM; IM |
Affiliation:
|
Department of Neurology, Massachusetts General Hospital, Boston 02114. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amino Acids
/
metabolism* Animals Brain / metabolism Decerebrate State Humans Huntington Disease / chemically induced, metabolism* Neurotransmitter Agents / metabolism* Quinolinic Acid Quinolinic Acids Rats Tissue Distribution |
| Grant Support | |
ID/Acronym/Agency:
|
IR23NS19867-1/NS/NINDS NIH HHS; MNINS 31862/NS/NINDS NIH HHS; NS 16367/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Amino Acids; 0/Neurotransmitter Agents; 0/Quinolinic Acids; 89-00-9/Quinolinic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expressed emotion and relapse in first episodes of schizophrenia. A rejoinder to Macmillan et al (19...
Next Document: Differential effects of norepinephrine on hippocampal complex-spike and theta-neurons.